查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612581

生物製药契约製造市场：按产品、供应商、服务、业务规模、治疗应用 - 2025-2030 年全球预测

Biopharmaceuticals Contract Manufacturing Market by Product (Biologics, Biosimilar), Source (Mammalian, Non-Mammalian), Services, Scale of Operation, Therapeutic Applications - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生物製药契约製造市场价值为182.7亿美元，预计到2024年将达到191.6亿美元，复合年增长率为5.14%，到2030年将达到259.5亿美元。

生物製药契约製造涉及将生物製药的生产外包给拥有製造复杂生物製药的基础设施和专业知识的专业公司。由于建造和维护符合严格监管标准的製造设施成本高昂且复杂，因此该模型是必要的。应用包括生产单株抗体、疫苗、基因和细胞治疗药物以及重组蛋白，最终用途广泛，包括製药公司、医院和研究机构。该市场呈现出显着的成长要素，例如慢性病的流行、对生技药品和生物仿製药的需求不断增加、製造技术的进步以及生物製药公司与契约製造製造商之间的策略联盟。此外，向个人化医疗的转变和对医疗基础设施投资的增加带来了利润丰厚的机会。公司可以透过扩大产能、实施数位技术来优化流程以及获取能力来增强自身能力来利用这些优势。然而，高营运成本、复杂的监管环境和供应链中断等挑战可能会阻碍市场成长。此外，在满足不同客户需求的同时保持产品品质并确保扩充性仍然是一个关键问题。创新领域包括一次性技术、流程自动化和探索永续製造方法。公司应专注于与监管机构建立牢固的关係，并投资尖端基础设施，以降低风险并保持竞争优势。新药物输送系统的研究以及上下游製程的优化可能会成为进一步成长的驱动力。市场竞争激烈，少数主要企业占据重要市场占有率，而许多小公司则努力创新和扩张。总体而言，生物製药契约製造市场预示着巨大的成长机会，但需要采取策略方法来有效克服挑战并利用新机会。

主要市场统计
基准年[2023] 182.7亿美元
预测年份 [2024] 191.6亿美元
预测年份 [2030] 259.5亿美元
复合年增长率（%） 5.14%

市场动态：快速发展的生物製药契约製造市场的关键市场洞察

生物製药契约製造市场正在因供需的动态相互作用而发生转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病流行
    • CMO的增加和对先进製造技术的投资
    • 生物製药公司外包增加
  • 市场限制因素
    • 建立生物製药生产设施的成本高昂
  • 市场机会
    • 加大生医研发与製造投入
    • 全球对个人化医疗的兴趣日益浓厚
  • 市场挑战
    • 对 CMO 的严格监管要求

波特五力：驾驭生物製药契约製造市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生物製药契约製造市场的外部影响

外部宏观环境因素在塑造生物製药契约製造市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解生物製药契约製造市场的竞争状况

生物製药契约製造市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵供应商在生物製药契约製造市场的绩效评估

FPNV定位矩阵是评估生物製药契约製造市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製生物製药契约製造市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，生物製药契约製造市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病增加
      • CMO数量增加，先进製造技术投入加大
      • 生物製药公司外包增加
    • 抑制因素
      • 建立生物製药生产设施的成本高昂
    • 机会
      • 加大生医研发与製造投入
      • 个人化医疗的重要性在全球范围内日益增加。
    • 任务
      • 对 CMO 的严格监管要求
  • 市场区隔分析
    • 服务：利用关键分析和品管研究来满足监管标准激增
    • 业务规模：生物医药契约製造业务规模扩大
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章生物製药契约製造市场：副产品

  • 生物製药
    • 单株抗体
    • 重组蛋白
    • 疫苗
  • 生物相似药

第七章生物製药契约製造市场：依来源分类

  • 哺乳动物的
  • 非哺乳动物

第八章生物製药契约製造市场：依服务分类

  • 分析和品管研究
  • 填充和整理操作
  • 包裹
  • 製程开发
    • 下游
    • 上游

第九章按业务规模分類的生物製药契约製造市场

  • 临床
  • 商业的

第十章 生物製药契约製造市场处理申请

  • 心血管疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 眼科
  • 呼吸系统疾病

第十一章 美洲生物製药契约製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章 亚太生物製药契约製造市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲生物製药契约製造市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • SwiftPharma 和 PlantForm Corporation 旨在透过一项新的植物来源相似药契约製造协议来开发重磅癌症治疗药物。
    • 三星生物製品扩大与百时美施贵宝的战略製造协议
    • Hikma 与 SK Biopharmaceuticals 结成策略联盟
  • 战略分析和建议

公司名单

  • 3P Biopharmaceuticals
  • AbbVie, Inc.
  • Aenova Group GmbH
  • AGC Biologics
  • Ajinomoto Co., Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Celonic AG
  • FUJIFILM Diosynth Biotechnologies
  • INCOG BioPharma Services, Inc.
  • JRS PHARMA GmbH+Co. KG
  • KBI Biopharma Inc
  • Lonza AG
  • Merck KGaA
  • Pressure BioSciences, Inc. by Emergent Health Corp.
  • ProBioGen AG
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics, Inc.
Product Code: MRR-8C74ADFC15ED

The Biopharmaceuticals Contract Manufacturing Market was valued at USD 18.27 billion in 2023, expected to reach USD 19.16 billion in 2024, and is projected to grow at a CAGR of 5.14%, to USD 25.95 billion by 2030.

Biopharmaceuticals contract manufacturing involves outsourcing the production of biopharmaceuticals to specialized companies that have the infrastructure and expertise to manufacture complex biological products. This model is necessary due to the high cost and complexity of building and maintaining manufacturing facilities that comply with stringent regulatory standards. Applications include the production of monoclonal antibodies, vaccines, gene and cell therapies, and recombinant proteins, with end-use spanning pharmaceutical companies, hospitals, and research institutions. The market exhibits significant growth factors, including the increasing prevalence of chronic diseases, the rising demand for biologics and biosimilars, advancements in manufacturing technology, and strategic partnerships between biopharma companies and contract manufacturers. Additionally, the shift towards personalized medicine and increased investment in healthcare infrastructure present lucrative opportunities. Companies can leverage these by expanding capacities, embracing digital technologies for process optimization, and engaging in mergers and acquisitions to enhance capabilities. However, challenges such as high operational costs, complex regulatory landscapes, and supply chain disruptions may hinder market growth. Moreover, maintaining product quality and ensuring scalability while meeting diverse client requirements remain key concerns. Innovation areas include exploring single-use technologies, process automation, and sustainable manufacturing practices. Companies should focus on building strong relationships with regulatory bodies and investing in state-of-the-art infrastructure to mitigate risks and maintain competitive advantage. Research into novel drug delivery systems and optimization of upstream and downstream processes could drive further growth. The market is primarily competitive, with a few key players holding substantial market share while numerous smaller companies strive to innovate and expand. Overall, the biopharmaceuticals contract manufacturing market offers substantial growth prospects, yet requires a strategic approach to navigate challenges effectively and capitalize on emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 18.27 billion
Estimated Year [2024] USD 19.16 billion
Forecast Year [2030] USD 25.95 billion
CAGR (%) 5.14%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biopharmaceuticals Contract Manufacturing Market

The Biopharmaceuticals Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of chronic diseases
    • Increasing number of CMOs and rising investments in advanced manufacturing technologies
    • Rising outsourcing by biopharmaceutical companies
  • Market Restraints
    • High price of setting up a production facility for biopharmaceuticals
  • Market Opportunities
    • Increasing investments in biopharmaceutical R&D and manufacturing
    • Growing emphasis on personalized medicine globally
  • Market Challenges
    • Stringent regulatory requirements for CMOs

Porter's Five Forces: A Strategic Tool for Navigating the Biopharmaceuticals Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biopharmaceuticals Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biopharmaceuticals Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biopharmaceuticals Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biopharmaceuticals Contract Manufacturing Market

A detailed market share analysis in the Biopharmaceuticals Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biopharmaceuticals Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biopharmaceuticals Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biopharmaceuticals Contract Manufacturing Market

A strategic analysis of the Biopharmaceuticals Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biopharmaceuticals Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include 3P Biopharmaceuticals, AbbVie, Inc., Aenova Group GmbH, AGC Biologics, Ajinomoto Co., Inc., Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Celonic AG, FUJIFILM Diosynth Biotechnologies, INCOG BioPharma Services, Inc., JRS PHARMA GmbH + Co. KG, KBI Biopharma Inc, Lonza AG, Merck KGaA, Pressure BioSciences, Inc. by Emergent Health Corp., ProBioGen AG, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific Inc., Toyobo Co., Ltd., and WuXi Biologics, Inc..

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biologics and Biosimilar. The Biologics is further studied across Monoclonal Antibodies, Recombinant Proteins, and Vaccines.
  • Based on Source, market is studied across Mammalian and Non-Mammalian.
  • Based on Services, market is studied across Analytical & QC studies, Fill & Finish Operations, Packaging, and Process Development. The Process Development is further studied across Downstream and Upstream.
  • Based on Scale of Operation, market is studied across Clinical and Commercial.
  • Based on Therapeutic Applications, market is studied across Cardiovascular Diseases, Infectious Disease, Neurology, Oncology, Ophthalmology, and Respiratory Disorder.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases
      • 5.1.1.2. Increasing number of CMOs and rising investments in advanced manufacturing technologies
      • 5.1.1.3. Rising outsourcing by biopharmaceutical companies
    • 5.1.2. Restraints
      • 5.1.2.1. High price of setting up a production facility for biopharmaceuticals
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments in biopharmaceutical R&D and manufacturing
      • 5.1.3.2. Growing emphasis on personalized medicine globally
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for CMOs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Services: Proliferating utilization of analytical and QC studies critical for meeting regulatory standards
    • 5.2.2. Scale of Operation: Evolving commercial scale of operation for biopharmaceuticals contract manufacturing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biopharmaceuticals Contract Manufacturing Market, by Product

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. Monoclonal Antibodies
    • 6.2.2. Recombinant Proteins
    • 6.2.3. Vaccines
  • 6.3. Biosimilar

7. Biopharmaceuticals Contract Manufacturing Market, by Source

  • 7.1. Introduction
  • 7.2. Mammalian
  • 7.3. Non-Mammalian

8. Biopharmaceuticals Contract Manufacturing Market, by Services

  • 8.1. Introduction
  • 8.2. Analytical & QC studies
  • 8.3. Fill & Finish Operations
  • 8.4. Packaging
  • 8.5. Process Development
    • 8.5.1. Downstream
    • 8.5.2. Upstream

9. Biopharmaceuticals Contract Manufacturing Market, by Scale of Operation

  • 9.1. Introduction
  • 9.2. Clinical
  • 9.3. Commercial

10. Biopharmaceuticals Contract Manufacturing Market, by Therapeutic Applications

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Infectious Disease
  • 10.4. Neurology
  • 10.5. Oncology
  • 10.6. Ophthalmology
  • 10.7. Respiratory Disorder

11. Americas Biopharmaceuticals Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Biopharmaceuticals Contract Manufacturing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. SwiftPharma and PlantForm Corporation target blockbuster cancer drug with new contract manufacturing agreement for plant-made biosimilars
    • 14.3.2. Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb
    • 14.3.3. Hikma and SK Biopharmaceuticals enter a strategic partnership
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3P Biopharmaceuticals
  • 2. AbbVie, Inc.
  • 3. Aenova Group GmbH
  • 4. AGC Biologics
  • 5. Ajinomoto Co., Inc.
  • 6. Aurobindo Pharma Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cambrex Corporation
  • 9. Catalent, Inc.
  • 10. Celonic AG
  • 11. FUJIFILM Diosynth Biotechnologies
  • 12. INCOG BioPharma Services, Inc.
  • 13. JRS PHARMA GmbH + Co. KG
  • 14. KBI Biopharma Inc
  • 15. Lonza AG
  • 16. Merck KGaA
  • 17. Pressure BioSciences, Inc. by Emergent Health Corp.
  • 18. ProBioGen AG
  • 19. Rentschler Biopharma SE
  • 20. Samsung Biologics
  • 21. Thermo Fisher Scientific Inc.
  • 22. Toyobo Co., Ltd.
  • 23. WuXi Biologics, Inc.

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RESPIRATORY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING